Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack

Stroke

Volumn 34, Issue 1, 2003, Pages 105-110

  Lalouschek, Wolfgang ^a   Lang, Wilfried ^a   Greisenegger, Stefan ^a   Müllner, Marcus ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lipids; Prevention; Statins; Stroke

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; MALE; MYOCARDIAL INFARCTION;

EID: 0037229193     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000048865.79221.4D     Document Type: Article

References (34)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
2. Crouse JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157:1305-1310.
3. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28:946-950.
4. Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis. 2000;10:85-92.
5. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387-392.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
7. Wolf P, Clagett G, Easton J, Goldstein L, Gorelick P, Kelly-Hayes M, Sacco R, Whisnant J. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 1999;30:1991-1994.
8. Department of Health. National service framework for coronary heart disease. Available at: http://www.doh.gov.uk/nsf/coronarych2.htm. Accessed November 30, 2000.
9. Wade DT, for the Intercollegiate Working Party for Stroke. National clinical guidelines for stroke. Royal College Physicians of London. Available at http://www.rcplondon.ac.uk). Accessed November 30, 2000.
10. Sandercock P. Statins for stroke prevention? Lancet. 2001;357:1548-1549.
11. Oliver MF. Cholesterol and strokes: cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ. 2000;320:459-460.
12. Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology. 2001;57:S35-s44.
13. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
14. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC, Alexander CM, Londhe A, Lulla A, Simpson RJ. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
15. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 1998;98:851-855.
16. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238-1244.
17. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14:711-717.
18. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada: Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Arch Intern Med. 2000;160:343-347.
19. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation. 2001;103:2768-2770.
20. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-58.
21. Hankey GJ, Warlow CP. Transient Ischaemic Attacks of the Brain and Eye. London, UK: WB Saunders; 1994.
22. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
23. Burn J, Dennis M, Bamford J. Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. Stroke. 1994;25:333-337.
24. Lang W, Lalouschek W, for the Vienna Stroke Study Group. The Vienna Stroke Registry: objectives and methodology. Wien Klin Wochenschr. 2001;113:141-147.
25. Lalouschek W, Lang W, Müllner M, for the Vienna Stroke Study Group. Current strategies of secondary prevention after a cerebrovascular event: the Vienna Stroke Registry. Stroke. 2001;32:2860-2866.
26. Stata Statistical Sofnvare: Release 7, Volume 4. College Station, Tex: Stata Corp; 2000:377-385.
27. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EER. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
28. Malach M, Quinley J, Imperato PJ, Wallen M. Improving lipid evaluation and management in Medicare patients hospitalized for acute myocardial infarction. Arch Intern Med. 2001;161:839-844.
29. Fonarow GC, French WJ, Parsons LS. Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38-44.
30. Wienbergen H, Schiele R, Gitt AK, Schneider S, Heer T, Gohlke H, Gottwik M, Thiele R, Keysser M, Horsch A, Weizel A, Senges J. Aktuelle Verordnungspraxis von CSE-Hemmem bei Entlassung aus der Klinik nach akutem Myokardinfarkt. Z Kardiol. 2001;90:394-400.
31. Nass C, Allen J, Jermyn R, Fleischer L. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral artery disease. Vasc Med. 2001;6:35-41.
32. Bismuth J, Klitfod L, Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. 2001;21:143-146.
33. Hirsch AT, Criqui MH, Treat Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection. awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
34. Peterson ED, Shaw LJ, Califf RM. Risk stratification after myocardial infarction. Ann Intern Med. 1997;126:561-582.